<?xml version="1.0" encoding="UTF-8"?> 
<DIV8 N="4.100" TYPE="SECTION" hierarchy_metadata="{&quot;path&quot;:&quot;/on/_SUBSTITUTE_DATE_/title-38/section-4.100&quot;,&quot;citation&quot;:&quot;38 CFR 4.100&quot;}">
<HEAD>รยง 4.100 Application of the general rating formula for diseases of the heart.</HEAD>
<P>(a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.</P>
<P>(b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:</P>
<P>(1) When there is a medical contraindication.</P>
<P>(2) When a 100% evaluation can be assigned on another basis.</P>
<SECAUTH TYPE="N">(Authority: 38 U.S.C. 1155)
</SECAUTH>
<CITA TYPE="N">[71 FR 52460, Sept. 6, 2006, as amended at 86 FR 54093, Sept. 30, 2021; 86 FR 67654, Nov. 29, 2021]
</CITA>
</DIV8>
